We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Hutchmed (china) Limited | HCM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 14.00 | 4.14% | 352.00 | 16:35:27 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 348.00 | 342.00 | 353.00 | 352.00 | 338.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 10/5/2024 20:21 by 1jat The company will need to think about how it deploys excess capital…..It looks likely they already have a buffer of ~US$200-300m in excess cash.A dividend of 1HKD/10p would cost about HKD850m / £85m US$110m and is likely affordable. However their main shareholders may not be than interested in a cash return and prefer buy backs. Management will also be able to fund M&A (I include in-licensing) to expand the business and potentially take on debt to fund itself. Lots of good problems for management to ponder. |
Posted at 10/5/2024 07:50 by 1jat LaudersThe sales report from Takeda was IMO a very positive one. They reported FY sales of 10.1bn JPY which is approx $65m, with 15m in 2023, that means Pts signed up for $50m in Q1. They are still building the book and have not reached a steady state when new patients are matched by patients coming off the medication. The $50m is approximately adding a net $5m of new sales each month which adds $30m to revenue each quarter in the short term and then the increment will start to tail off as equilibrium is reached. The maths suggests a likely sales trajectory in the US for 2024 Q/ly sales of 50 80 110 140 which totals $380m. We can watch that develop with the HY results at the end of July, but I would be hopeful that Takeda generates $350m of US revenue this year which will bring HCM $50 of royalty payments. EU approval should come in July with sales in the higher volume but maybe price limited markets following…..TH Japan approval around the end of the year with sales starting in 2025. Other markets to follow using these approvals as a base. I can see HCM getting $150-200m in royalty payments in 2026 which will last for a few years. |
Posted at 09/5/2024 09:33 by lauders Wonder why the rise today? Could it be Takeda related? Sales of Fruzaqla.Doubt it is related to the news yesterday: Hong Kong, Shanghai & Florham Park, NJ - Wednesday, May 8, 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. Interesting to see she is the chairman of the Listing Committee of The Stock Exchange of Hong Kong Limited though. |
Posted at 26/4/2024 17:15 by dbadvn US investors so spooked over China that all they are looking at is the money.When the cash starts tocome in they will react. In the meantime HCM remains a huge bargain. |
Posted at 25/4/2024 09:30 by 1jat AZ reported Q1 Orpathys sales up 43% (48% at CER). HCM gets a large % of the revenue in royalties and manufacturing fees.Sales continue to build after inclusion in NRDL. |
Posted at 02/4/2024 06:00 by lauders More good news from HCM today: HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status |
Posted at 12/3/2024 09:43 by 1jat I am not sure these moves on no news really mean anything…and could well be reversed tomorrow when the market takes fright at some statement coming from US/China that indicates more restrictions.The next news I will be looking for will be from Takeda… Their annual results are due in early/mid May and will contain the $15m sales from 2023 disclosed by HCM and the first three months of 2024. There may have been some stocking within the $15m and conversion of those on early access programs, but I hope they can sell $30m in Q1 and build to a $50m/quarter during 2024. This would give US in market sales of $150-180 and a $20m royalty (pure profit) to HCM (plus manufacturing fees). It was interesting to see in the company presentation that Europe is potentially a much larger market than the US. It did not appear that the EMA was giving priority status, so they may take longer than the US to approve…that will also be good news when it comes. |
Posted at 29/1/2024 14:46 by nerdofsteel "But hcm still irritates you"not really, I was just posting an observation about geo-politics at play here and yes I have sold, but I may well buy back in if things begin to improve. In the meantime I've made a packet on Nvidia, more in a month than I have being invested in HCM over 7 years... |
Posted at 28/1/2024 18:23 by 1jat Lauders - I agree with your sentiment but it could be some time in coming… the macro environment is again at play - I read a US congressman has tabled a bill to sanction certain Chinese Biopharma due to links to the China Army….which cannot be helping US investors.I doubt many investors in smaller pharma are actually expecting/wanting them to transition into self supporting larger pharma cos. It is not clear what CKHH position is….they seem to be happy to hold and see the company grow - they dont currently need any cash from their stake, this effectively means HCM is not for sale. If the Vodafone/3 deal goes through CKHH will pocket a couple of Billion and have options to sell out in 2-3 years…. I expect there will be M&A within China biopharma soon…..many companies have cash for a couple of years if fund raising becomes more difficult they will have to be sold…HCM may get to self sustainability before this happens which will put them into a stronger position to buy. |
Posted at 22/1/2024 22:45 by mcmather US closed -7.50%. Will we see any response from the company?There appeared to be support on the US weekly at 14.48ish. Hmmmm. FWIW: "The 55 rating InvestorsObserver gives to HUTCHMED (China) Ltd (HCM) stock puts it near the top of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 80 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, HCM’s 55 overall rating means the stock scores better than 55 percent of all stocks...Over the past year the S&P 500 has risen 20.68% while HCM has fallen -26.98%" |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
